Other limitations include the fact that there is no clear definition of refractory membranous nephropathy, the definition of remission is very heterogeneous, the baseline clinical characteristics of the patients are very heterogeneous, and PLA2R antibody titres have not been reported in all the studies. This evidence concerns the gene PLA2R1 and membranous glomerulonephritis.